<DOC>
	<DOCNO>NCT02950103</DOCNO>
	<brief_summary>Synthetic phosphoethanolamine primary amine critical role biosynthesis cell membrane . Pre-clinical model show potential anticancer activity .</brief_summary>
	<brief_title>Efficacy Safety Synthetic Phosphoethanolamine Solid Tumor Patients</brief_title>
	<detailed_description>Phase II multi-cohort study base two-stage Simon design . The primary goal study response rate 8 week participant advance solid tumor treat synthetic phosphoethanolamine , define Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v 1.1 ) specific criterion prostate cancer .</detailed_description>
	<criteria>Histologically proven advanced solid tumor patient ( recurrent metastatic ) , amenable curative therapy . Patients must progress standard treatment proven prolong survival standard treatment exists . Tumor type include head neck squamous cell carcinoma , nonsmall cell lung cancer , colorectal adenocarcinoma , breast cancer , cervix cancer , prostate cancer , melanoma , pancreas adenocarcinoma , gastric adenocarcinoma , hepatocellular carcinoma No concurrent active systemic treatment Measurable disease RECIST v1.1 Clinical radiological progression last three month Eastern Cooperative Oncology Group Performance Status 01 Ability consent Adequate organ function Life expectancy great 12 week Ability swallow No previous malignancy last 5 year Pregnancy Corticosteroid therapy prostate cancer Uncontrolled comorbidity Known hepatitis B , C HIV Central nervous system involvement , except control symptom without corticosteroid Previous use phosphoethalonamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>phase II</keyword>
	<keyword>phosphoethanolamine</keyword>
</DOC>